LT2575884T - Panaudojimai ir kompozicijos, skirti pūlingo hidradenito (hs) gydymui - Google Patents
Panaudojimai ir kompozicijos, skirti pūlingo hidradenito (hs) gydymuiInfo
- Publication number
- LT2575884T LT2575884T LTEP11790495.3T LT11790495T LT2575884T LT 2575884 T LT2575884 T LT 2575884T LT 11790495 T LT11790495 T LT 11790495T LT 2575884 T LT2575884 T LT 2575884T
- Authority
- LT
- Lithuania
- Prior art keywords
- compositions
- treatment
- hidradenitis suppurativa
- suppurativa
- hidradenitis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35112510P | 2010-06-03 | 2010-06-03 | |
US201161430645P | 2011-01-07 | 2011-01-07 | |
US201161474764P | 2011-04-13 | 2011-04-13 | |
PCT/US2011/039135 WO2011153477A2 (en) | 2010-06-03 | 2011-06-03 | Uses and compositions for treatment of hidradenitis suppurativa (hs) |
Publications (1)
Publication Number | Publication Date |
---|---|
LT2575884T true LT2575884T (lt) | 2018-09-25 |
Family
ID=45064648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP11790495.3T LT2575884T (lt) | 2010-06-03 | 2011-06-03 | Panaudojimai ir kompozicijos, skirti pūlingo hidradenito (hs) gydymui |
Country Status (17)
Country | Link |
---|---|
US (3) | US8747854B2 (ru) |
EP (1) | EP2575884B1 (ru) |
JP (2) | JP5944382B2 (ru) |
CN (2) | CN105056232A (ru) |
CA (1) | CA2801917C (ru) |
CY (1) | CY1120664T1 (ru) |
DK (1) | DK2575884T3 (ru) |
ES (1) | ES2685607T3 (ru) |
HR (1) | HRP20181598T1 (ru) |
HU (1) | HUE039740T2 (ru) |
LT (1) | LT2575884T (ru) |
MX (1) | MX2012014080A (ru) |
PL (1) | PL2575884T3 (ru) |
PT (1) | PT2575884T (ru) |
RS (1) | RS57543B1 (ru) |
SI (1) | SI2575884T1 (ru) |
WO (1) | WO2011153477A2 (ru) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
NZ512006A (en) | 1996-02-09 | 2005-05-27 | Abbott Biotech Ltd | Medical treatment with human TNF-alpha antibodies |
CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
US8715664B2 (en) | 2005-05-16 | 2014-05-06 | Abbvie Biotechnology Ltd. | Use of human TNFα antibodies for treatment of erosive polyarthritis |
TWI439284B (zh) | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | 用於治療TNFα相關失調症之多重可變劑量療法 |
GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
SG169361A1 (en) | 2005-11-01 | 2011-03-30 | Abbott Biotech Ltd | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
CA2647029A1 (en) | 2006-04-05 | 2007-10-18 | Abbott Biotechnology Ltd. | Antibody purification |
US9605064B2 (en) * | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
EP2010214A4 (en) * | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
WO2007120626A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of ankylosing spondylitis |
US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
WO2008005315A2 (en) | 2006-06-30 | 2008-01-10 | Abbott Biotechnology Ltd. | Automatic injection device |
EP2684895A1 (en) | 2006-10-27 | 2014-01-15 | AbbVie Biotechnology Ltd | Crystalline anti-hTNFalpha antibodies |
EP2171451A4 (en) * | 2007-06-11 | 2011-12-07 | Abbott Biotech Ltd | METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS |
EP2173380A4 (en) * | 2007-07-13 | 2011-08-31 | Abbott Biotech Ltd | METHOD AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa HEMMER |
SG183709A1 (en) * | 2007-08-08 | 2012-09-27 | Abbott Lab | Compositions and methods for crystallizing antibodies |
NZ622583A (en) * | 2007-11-30 | 2015-08-28 | Abbvie Biotechnology Ltd | Protein formulations and methods of making same |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
CN105056232A (zh) * | 2010-06-03 | 2015-11-18 | 阿布维生物技术有限公司 | 用于治疗化脓性汗腺炎(hs)的用途和组合物 |
KR20130108305A (ko) | 2010-08-23 | 2013-10-02 | 엑스바이오테크, 인크. | 종양성 질병들에 대한 치료 |
AU2011325974B2 (en) | 2010-11-11 | 2016-10-27 | Abbvie Biotechnology Ltd. | Improved high concentration anti-TNFalpha antibody liquid formulations |
EP2749305B1 (en) | 2011-01-24 | 2017-11-01 | AbbVie Biotechnology Ltd | Automatic injection devices having overmolded gripping surfaces |
WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
EP2890782A1 (en) | 2012-09-02 | 2015-07-08 | AbbVie Inc. | Methods to control protein heterogeneity |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
EP2934587A4 (en) | 2012-12-18 | 2016-08-03 | Merck Sharp & Dohme | LIQUID FORMULATIONS FOR ANTI-TNFALPHA ANTIBODY |
CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
CN106170298B (zh) | 2013-10-16 | 2024-01-09 | 前瞻疗法公司 | 用于提高抗体稳定性的缓冲液制剂 |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
US10696735B2 (en) | 2015-01-21 | 2020-06-30 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
EP3078675A1 (en) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induction dosing regimen for the treatment of tnf alpha mediated disorders |
WO2017136433A1 (en) | 2016-02-03 | 2017-08-10 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
CN109476699B (zh) | 2016-06-02 | 2021-10-12 | 艾伯维公司 | 糖皮质激素受体激动剂及其免疫偶联物 |
DK3538118T3 (da) | 2016-11-11 | 2021-05-25 | Sjaellands Univ Dermatologisk Afdeling | Levende saprofytbakterier til anvendelse til behandling af hidradenitis suppurativa |
KR20190117579A (ko) | 2017-02-16 | 2019-10-16 | 엑스바이오테크, 인크. | 화농성 한선염의 치료 |
US20200277369A1 (en) * | 2017-11-20 | 2020-09-03 | Novartis Ag | Method of treating hidradentitis suppurativa with il-17 antagonists |
HUE054428T2 (hu) | 2017-12-01 | 2021-09-28 | Abbvie Inc | Glükokortikoid receptor agonista és annak immunkonjugátumai |
WO2019130215A1 (en) * | 2017-12-27 | 2019-07-04 | To Pharmaceuticals Llc | Cannabis compositions for the treatment of inflammatory skin disorders |
TWI737000B (zh) * | 2018-10-22 | 2021-08-21 | 美商美國禮來大藥廠 | 用於治療化膿性汗腺炎之泛-elr+cxc趨化介素抗體 |
CN115802888A (zh) * | 2020-06-17 | 2023-03-14 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
IL308134A (en) * | 2021-06-22 | 2023-12-01 | Novartis Ag | BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF HIDRADENITIS SUPPURATIVA |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
DE68925966T2 (de) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US6448380B2 (en) | 1989-08-07 | 2002-09-10 | Peptech Limited | Tumor necrosis factor antibodies |
US5959087A (en) | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
AU630497B2 (en) | 1989-09-05 | 1992-10-29 | Immunex Corporation | Tumor necrosis factor-alpha and -beta receptors |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
EP0575485A1 (en) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Process for the development of binding mini-proteins |
WO1992016553A1 (en) | 1991-03-18 | 1992-10-01 | New York University | Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
ATE269401T1 (de) | 1991-04-10 | 2004-07-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
JP3251587B2 (ja) | 1992-04-02 | 2002-01-28 | スミスクライン・ビーチャム・コーポレイション | 炎症疾患の治療および腫瘍壊死因子の産生阻害に有用な化合物 |
CA2123593C (en) | 1992-09-15 | 2000-03-14 | Craig A. Smith | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
NZ512006A (en) | 1996-02-09 | 2005-05-27 | Abbott Biotech Ltd | Medical treatment with human TNF-alpha antibodies |
US6537549B2 (en) | 1999-02-24 | 2003-03-25 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
US6177077B1 (en) | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
UA81743C2 (ru) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО ЧЕЛОВЕКА, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С ФАКТОРОМ НЕКРОЗА ОПУХОЛЕЙ АЛЬФА (ФНПα), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ, И СПОСОБ ЛЕЧЕНИЯ РЕВМАТОИДНОГО АРТРИТА |
US7833525B2 (en) | 2000-12-28 | 2010-11-16 | Bhami Shenoy | Crystals of whole antibodies and fragments thereof and methods for making and using them |
BR0206160A (pt) | 2001-05-25 | 2004-10-26 | Abbott Gmbh & Co Kg | Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos |
CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US20030161828A1 (en) | 2002-02-19 | 2003-08-28 | Abbott Gmbh & Co. Kg | Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure |
US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
US20040009172A1 (en) | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
US20090280065A1 (en) | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
US8715664B2 (en) | 2005-05-16 | 2014-05-06 | Abbvie Biotechnology Ltd. | Use of human TNFα antibodies for treatment of erosive polyarthritis |
US20070202104A1 (en) | 2002-07-19 | 2007-08-30 | Abbott Laboratories S.A. | Treatment of spondyloarthropathies using TNFalpha inhibitors |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
TWI439284B (zh) | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | 用於治療TNFα相關失調症之多重可變劑量療法 |
CN1988918A (zh) * | 2004-04-09 | 2007-06-27 | 艾博特生物技术有限公司 | 用于治疗TNFα-相关病症的多变剂量方案 |
EP1807111A4 (en) | 2004-10-08 | 2009-05-27 | Abbott Biotech Ltd | SYNCYTIAL RESPIRATORY VIRUS INFECTION (RSV) |
US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
SG169361A1 (en) | 2005-11-01 | 2011-03-30 | Abbott Biotech Ltd | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
CA2647029A1 (en) | 2006-04-05 | 2007-10-18 | Abbott Biotechnology Ltd. | Antibody purification |
US20080118496A1 (en) | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
WO2007120626A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of ankylosing spondylitis |
US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
WO2008063213A2 (en) | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
EP2010214A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
US20090317399A1 (en) | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
US20080131374A1 (en) | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
US20080311043A1 (en) | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
WO2008005315A2 (en) | 2006-06-30 | 2008-01-10 | Abbott Biotechnology Ltd. | Automatic injection device |
SG10201510384UA (en) | 2006-09-13 | 2016-01-28 | Abbvie Inc | Cell culture improvements |
EP2684895A1 (en) | 2006-10-27 | 2014-01-15 | AbbVie Biotechnology Ltd | Crystalline anti-hTNFalpha antibodies |
EP2679996A1 (en) | 2007-05-31 | 2014-01-01 | AbbVie Inc. | Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders |
EP2152318A4 (en) | 2007-06-01 | 2011-12-07 | Abbott Biotech Ltd | COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE |
EP2171451A4 (en) | 2007-06-11 | 2011-12-07 | Abbott Biotech Ltd | METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS |
EP2173380A4 (en) | 2007-07-13 | 2011-08-31 | Abbott Biotech Ltd | METHOD AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa HEMMER |
SG183709A1 (en) | 2007-08-08 | 2012-09-27 | Abbott Lab | Compositions and methods for crystallizing antibodies |
EP2193145A4 (en) | 2007-08-28 | 2011-05-18 | Abbott Biotech Ltd | COMPOSITIONS AND METHODS COMPRISING BINDING PROTEINS FOR ADALIMUMAB |
NZ622583A (en) | 2007-11-30 | 2015-08-28 | Abbvie Biotechnology Ltd | Protein formulations and methods of making same |
CA2710779C (en) * | 2007-12-31 | 2017-06-20 | Bayer Schering Pharma Aktiengesellschaft | Antibodies to tnf.alpha. |
CA2710333A1 (en) | 2008-01-03 | 2009-07-09 | Abbott Biotechnology Ltd. | Predicting long-term efficacy of a compound in the treatment of psoriasis |
SG187473A1 (en) | 2008-01-15 | 2013-02-28 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
BRPI0906490A2 (pt) | 2008-01-15 | 2015-07-14 | Abbott Lab | Vetores de expressão de mamífero melhorados e uso dos mesmos |
EP2271671A2 (en) | 2008-03-24 | 2011-01-12 | Abbott Biotechnology Ltd. | Tnf-alpha inhibitors for treating bone loss |
CN101684156B (zh) * | 2008-09-27 | 2011-12-28 | 苏州工业园区晨健抗体组药物开发有限公司 | 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用 |
CN102458517B (zh) | 2009-04-29 | 2014-07-23 | 阿布维生物技术有限公司 | 自动注射装置 |
EP2427211A4 (en) | 2009-05-04 | 2013-05-01 | Abbott Biotech Ltd | STABLE FORMULATIONS WITH HIGH PROTEIN CONCENTRATION OF ANTI-TNF-ALPHA HUMAN ANTIBODIES |
IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
MX2012008985A (es) | 2010-02-02 | 2012-09-07 | Abbott Biotech Ltd | Metodos y composiciones para predecir la capacidad de respuesta al tratamiento con el inhibidor de tnf-alfa. |
CN105056232A (zh) * | 2010-06-03 | 2015-11-18 | 阿布维生物技术有限公司 | 用于治疗化脓性汗腺炎(hs)的用途和组合物 |
-
2011
- 2011-06-03 CN CN201510560983.9A patent/CN105056232A/zh active Pending
- 2011-06-03 WO PCT/US2011/039135 patent/WO2011153477A2/en active Application Filing
- 2011-06-03 DK DK11790495.3T patent/DK2575884T3/en active
- 2011-06-03 US US13/153,131 patent/US8747854B2/en active Active
- 2011-06-03 PT PT11790495T patent/PT2575884T/pt unknown
- 2011-06-03 EP EP11790495.3A patent/EP2575884B1/en active Active
- 2011-06-03 RS RS20180883A patent/RS57543B1/sr unknown
- 2011-06-03 HU HUE11790495A patent/HUE039740T2/hu unknown
- 2011-06-03 MX MX2012014080A patent/MX2012014080A/es active IP Right Grant
- 2011-06-03 LT LTEP11790495.3T patent/LT2575884T/lt unknown
- 2011-06-03 CA CA2801917A patent/CA2801917C/en active Active
- 2011-06-03 PL PL11790495T patent/PL2575884T3/pl unknown
- 2011-06-03 ES ES11790495.3T patent/ES2685607T3/es active Active
- 2011-06-03 SI SI201131570T patent/SI2575884T1/sl unknown
- 2011-06-03 CN CN201180035021.1A patent/CN103079594B/zh active Active
- 2011-06-03 JP JP2013513388A patent/JP5944382B2/ja active Active
-
2014
- 2014-05-28 US US14/289,115 patent/US9334320B2/en active Active
-
2016
- 2016-05-06 US US15/148,089 patent/US20170101465A1/en not_active Abandoned
- 2016-05-24 JP JP2016103023A patent/JP2016193916A/ja active Pending
-
2018
- 2018-09-07 CY CY181100938T patent/CY1120664T1/el unknown
- 2018-10-04 HR HRP20181598TT patent/HRP20181598T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
US8747854B2 (en) | 2014-06-10 |
EP2575884A4 (en) | 2013-12-04 |
US20150147335A1 (en) | 2015-05-28 |
US20110300151A1 (en) | 2011-12-08 |
CY1120664T1 (el) | 2019-12-11 |
CN103079594B (zh) | 2016-04-13 |
PT2575884T (pt) | 2018-10-31 |
US20170101465A1 (en) | 2017-04-13 |
MX2012014080A (es) | 2013-05-01 |
RS57543B1 (sr) | 2018-10-31 |
CN105056232A (zh) | 2015-11-18 |
DK2575884T3 (en) | 2018-09-03 |
WO2011153477A2 (en) | 2011-12-08 |
WO2011153477A3 (en) | 2012-03-15 |
JP2013533858A (ja) | 2013-08-29 |
CA2801917C (en) | 2017-04-25 |
ES2685607T3 (es) | 2018-10-10 |
SI2575884T1 (sl) | 2018-10-30 |
HRP20181598T1 (hr) | 2018-11-30 |
US9334320B2 (en) | 2016-05-10 |
HUE039740T2 (hu) | 2019-01-28 |
PL2575884T3 (pl) | 2018-12-31 |
EP2575884B1 (en) | 2018-07-18 |
CN103079594A (zh) | 2013-05-01 |
CA2801917A1 (en) | 2011-12-08 |
EP2575884A2 (en) | 2013-04-10 |
JP2016193916A (ja) | 2016-11-17 |
JP5944382B2 (ja) | 2016-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181598T1 (hr) | Uporaba i pripravci za liječenje hidradenitis suppurativa (hs) | |
IL254909B (en) | Preparations and methods for treating edible material and their substrates | |
EP2603202A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES | |
ZA201208642B (en) | Treatment of modified atmosphere packaging | |
EP2391344A4 (en) | COMPOSITIONS FOR THE TREATMENT OF NAILS AND SKIN | |
HK1178465A1 (en) | Composition for improving condition of skin | |
PL2512446T3 (pl) | Kompozycja transdermalnego hydrożelu z deksibuprofenem | |
EP2603193A4 (en) | COSMETIC SILICONE COMPOSITIONS AND USES THEREOF | |
EP2654745A4 (en) | COMPOSITION FOR TREATING SKIN CONDITIONS OF THE SKIN | |
EP2640782A4 (en) | Compositions and articles of manufacture containing siloxane | |
ZA201208413B (en) | Skin treatment composition | |
EP2544655A4 (en) | COMPOSITIONS AND METHODS FOR TREATING SKIN | |
IL225793A0 (en) | Methods and preparations for curing insulin-related medical conditions | |
EP2566439A4 (en) | SKIN CARE COMPOSITIONS WITH 12-HYDROXYSTEARINIC ACID | |
GB0902040D0 (en) | Composition for treatment of skin | |
ZA201301936B (en) | Methods and compositions for treatment of diabetes and dyslipidemia | |
HUE038787T2 (hu) | Tripeptid készítmények és alkalmazásuk diabétesz kezelésére | |
IL225939A0 (en) | Preparations for the treatment of peripheral ulcers from a variety of sources | |
EP2601930A4 (en) | MEANS FOR INCREASING A BLEACHING EFFECT AND APPLYING THEREOF | |
EP2549867A4 (en) | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF INJURIES | |
ZA201208568B (en) | Skin treatment composition | |
EP2411020A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMORRHAGE | |
GB201010638D0 (en) | Composition for treatment of skin | |
PL2456445T3 (pl) | Środek do leczenia chorób skóry | |
IL212252A0 (en) | Oligonucleotide compositions and use thereof for prophylactic treatment of organophosphate poisoning |